Manufacturers report positive results from Phase 3 ADAPT-PO trial for oral tebipenem for complicated urinary tract infection and acute pyelonephritis

In this trial, oral tebipenem (a broad spectrum novel carbapenem) met its primary endpoint, demonstrating statistical non-inferiority vs IV ertapenem for combined clinical cure plus microbiologic eradication in complicated urinary tract infection and acute pyelonephritis.

Biospace Inc.